• Explore /
  • Poster
  • / Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Abstract Poster

Authors

null

Van K. Morris II

NRG Oncology, and University of Texas MD Anderson Cancer Center, Houston, TX;

Van K. Morris II, Greg Yothers , Scott Kopetz , Samuel A. Jacobs , Peter C. Lucas , Atif Iqbal , Patrick M Boland , Dustin A. Deming , Aaron James Scott , Howard John Lim , Theodore S. Hong , Norman Wolmark , Thomas J. George

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04068103

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS259)

DOI

10.1200/JCO.2023.41.4_suppl.TPS259

Abstract #

TPS259

Poster Bd #

P1

Abstract Disclosures

Similar Posters

First Author: Van K. Morris II

First Author: Van K. Morris II

First Author: Van K. Morris II

First Author: Van K. Morris II